NCT06714838View on ClinicalTrials.gov

Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy

PHASE3RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 16, 2024

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2028

Conditions
CIDP
Interventions
DRUG

Rituximab (Mabthera)

Rituximab will be administered in a hospital setting in the course of one day. It will be given intravenously, at time points baseline, week 2 and week 26.

Trial Locations (1)

1105AZ

RECRUITING

Amsterdam UMC, Amsterdam

Sponsors

Collaborators (1)

Erasmus Medical Center
All Listed Sponsors
collaborator

Stichting Treatmeds

UNKNOWN

collaborator

UMC Utrecht

OTHER

collaborator

Erasmus Medical Center

OTHER

lead

Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC)

OTHER

NCT06714838 - Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy | Biotech Hunter | Biotech Hunter